What is the most appropriate medication for chronic insomnia in a 65‑year‑old woman whose sleep disturbance is due to situational worry about her in‑laws and who declines regular anxiolytic therapy?

Best Medication for Situational Chronic Insomnia in a 65-Year-Old Woman

Start with a short-intermediate acting benzodiazepine receptor agonist (BzRA) such as zolpidem 5 mg or eszopiclone 1-2 mg at bedtime, used intermittently (3 nights per week or as needed) rather than nightly, combined with cognitive behavioral therapy for insomnia (CBT-I) if she's willing to engage in non-medication approaches.

Rationale for This Recommendation

Given your patient's age (65 years) and the situational nature of her insomnia, the guideline-based approach prioritizes safety while addressing her immediate sleep needs. The American Academy of Sleep Medicine guidelines 1 recommend short-intermediate acting BzRAs or ramelteon as first-line pharmacologic treatment for primary insomnia, with specific considerations for older adults.

Why BzRAs Are Appropriate Here

• First-line status: Guidelines consistently place BzRAs (zolpidem, eszopiclone, zaleplon, temazepam) as the initial pharmacologic choice 1, 2
• Age-appropriate dosing: For a 65-year-old woman, start with zolpidem 5 mg (not 10 mg) or eszopiclone 1 mg (not 2-3 mg) to minimize fall risk and cognitive impairment 3
• Intermittent dosing strategy: Since her insomnia is situational (worry about in-laws), prescribe for intermittent use (3 nights per week or as needed) rather than nightly 1. This reduces dependency risk and aligns with her perception that the problem may resolve

Specific Medication Choices in Order of Preference

1. Zolpidem 5 mg at bedtime - Short-acting, primarily for sleep onset, lower risk of next-day sedation 2
2. Eszopiclone 1-2 mg at bedtime - Covers both sleep onset and maintenance, no short-term usage restriction 2
3. Ramelteon 8 mg at bedtime - Melatonin receptor agonist with no abuse potential, though less effective than BzRAs 2

Why NOT Other Options

Avoid benzodiazepines (temazepam, triazolam): While effective, the 2020 VA/DoD guidelines 4 specifically recommend against benzodiazepines due to risks that substantially outweigh benefits in older adults—including falls, cognitive impairment, dependency, and respiratory depression.

Avoid trazodone: The 2017 AASM guideline 2 explicitly recommends against trazodone for insomnia treatment. Despite its widespread off-label use, evidence shows no difference from placebo in sleep efficiency or total sleep time, with concerning adverse effects 4.

Avoid antihistamines (diphenhydramine, doxylamine): Not recommended for chronic insomnia due to lack of efficacy data, anticholinergic effects particularly dangerous in older adults (Beers Criteria), and tolerance developing after 3-4 days 1, 4.

Avoid antipsychotics (quetiapine): No evidence supporting use, with serious harms including increased mortality risk in elderly patients 4.

Alternative: Dual Orexin Receptor Antagonists

If BzRAs are contraindicated or ineffective, consider suvorexant (start 5-10 mg in elderly) or newer agents like daridorexant. Recent evidence 5, 6 shows these are effective and generally safe in older adults with favorable side effect profiles compared to traditional hypnotics. The 2017 AASM guideline 2 suggests suvorexant for sleep maintenance insomnia.

Critical Safety Considerations for Your 65-Year-Old Patient

• Start low, go slow: Use half the standard adult dose given her age 3
• Screen for sleep apnea: BzRAs can worsen respiratory conditions; if she snores or has witnessed apneas, consider polysomnography first 1
• Fall risk assessment: Educate about getting up slowly at night, keeping pathways clear, avoiding alcohol
• Medication interactions: Review her current medications for CNS depressants 1
• Empty stomach dosing: Take medication on empty stomach for maximum effectiveness 1
• Time in bed: Ensure she allows adequate time (7-8 hours) before needing to be alert to avoid morning impairment 1

Essential Patient Education Points

Discuss with her 1:

1. Treatment goals: Intermittent use for situational stress, not long-term solution
2. Rebound insomnia: May occur if stopped abruptly after regular use
3. Complex behaviors: Rare but serious risk of sleep-driving, sleep-eating without memory
4. No alcohol: Absolutely avoid combining with alcohol
5. Tapering plan: When in-law situation resolves, taper gradually rather than stopping abruptly

Strongly Recommend Adding CBT-I

Even though she declined "regular anxiety medication," strongly encourage cognitive behavioral therapy for insomnia (CBT-I) 1, 7. This addresses the worry component without framing it as anxiety treatment:

• Sleep restriction therapy
• Stimulus control (bed only for sleep)
• Cognitive restructuring of catastrophic thoughts about sleep
• Can be delivered digitally if in-person access is limited 8

The 2008 AASM guideline 1 explicitly states that "short-term hypnotic treatment should be supplemented with behavioral and cognitive therapies when possible," and combination therapy facilitates eventual medication tapering 1.

Follow-Up Schedule

• Initial follow-up: 2-4 weeks to assess effectiveness, side effects, and proper use 1
• Ongoing monitoring: Every 4-8 weeks if continuing medication
• Reassess regularly: Is the situational stressor still present? Can medication be tapered?
• Lowest effective dose: Continuously attempt to use minimum effective dose 1

Common Pitfall to Avoid

Do not prescribe trazodone simply because "it's not a controlled substance" or "everyone uses it for sleep." This is poor practice not supported by evidence and carries real risks in older adults 2, 4. The controlled substance status of BzRAs reflects abuse potential but shouldn't prevent appropriate short-term, intermittent use in a 65-year-old woman with situational insomnia.